safety and efficacy study in management of Dermatitis
- Conditions
- Health Condition 1: L300- Nummular dermatitis
- Registration Number
- CTRI/2019/09/021466
- Lead Sponsor
- The Himalaya Drug Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Both male and female subject presenting with signs and symptoms of various dermatitis such as allergic, irritant, nummular, dyshidrosis(pompholyx) and pityriasis alba
Subject presenting with signs and symptoms of dermatitis such as like, pain, itching, burning, dryness, redness, induration, peeling, scaling, fissure, vesicles and bullae
Both male and female subject aged between 18-65 years, both inclusive at the time of consent
Investigators Static Global Assessment ISGA score of 2 mild or 3 moderate
Subject has contact dermatitis covering between 0.5% to 10% of the total Body Surface Area (BSA at Screening/Day 1.
Subject must be willing and able to avoid the causative allergens during the study.
Clinically infective and atopic dermatitis
Any dermatological condition other than irritant dermatitis
History of allergy or sensitivity to investigational product
Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of IP
Subjects using steroids or any other medications for the same indication in last 2 weeks and not willing to discontinue the treatment
Pregnant and lactating women
History of ongoing, chronic or recurrent infectious disease / lymphoproliferative disease or history of malignancy of any organ system within the past 5 years
History of Alcohol or smoking abuse
Patients unwilling to provide informed consent or abide by the requirements of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method